#news #biotech New CEO axes 30% of Seres’ workforce to refocus on ‘high priority’ late-stage efforts

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: New CEO axes 30% of Seres’ workforce to refocus on ‘high priority’ late-stage efforts .Seres Therapeutics has cut about 30% of its workforce and said goodbye to its chief scientific officer as it narrows its clinical efforts. It will instead focus on what it described as its “highest priority” late-stage microbiome programs for ulcerative colitis and C. difficile infections, as well as a planned immuno-oncology study.

from FierceBiotech: Biotech http://bit.ly/2TFlNxB